课题基金 / 基金详情

Functionalization of LbL-Microcarriers as Drug Delivery System for Elastase Inhibitors and HOCl Scavengers for the Termination of Chronic Inflammation

Functionalization of LbL-Microcarriers as Drug Delivery System for Elastase Inhibitors and HOCl Scavengers for the Termination of Chronic Inflammation
LbL-微载体作为弹性蛋白酶抑制剂和 HOCl 清除剂的药物输送系统的功能化,用于终止慢性炎症
批准号:
199709420
负责人:
Privatdozentin Dr. Uta Reibetanz
金额:
$0.0万
依托单位:
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
2011
资助国家:
德国
项目状态:
已结题
起止时间:
2010-12-31 至 2017-12-31

项目摘要

项目成果

Privatdozentin Dr. Uta Reibetanz的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The treatment of chronic inflammation represents an important medical challenge in the modern world. The application of systemically acting pharmaceuticals is often accompanied by multiple side effects. Therefore, the development of new drug delivery systems has to consider targeted and locally sustained applications of pharmaceuticals with high efficiency and reduced side effects.Layer by Layer (LbL) coated microcarriers represent an excellent choice for the treatment of local inflammations occurring, for instance, in arthritic joints. The modular principle of construction, that is the step-wise adsorption of oppositely charged polyelectrolytes onto a spherical micro-template forming a multilayer for an integration of active agents, offers many advantages: Using biocompatible and biodegradable polymers, time controlled and sustained release of one or more active agents, specific cell targeting and high biocompatibility can be realized. The subject of this proposal is to continue the conceptual development and investigation of those specific carriers regarding the transport of antiinflammatory substances into inflamed tissues. Here, neutrophils are in the focus of the investigations: These immune cells generate continuously considerable amounts of aggressive enzymes which contribute to chronification and massive tissue destruction. A specific enzyme, elastase, plays a major role in these processes. For an effective inhibition, LbL microcarriers will be designed to promote intracellular and extracellular elastase inhibition by a1antitrypsin (AT) by only one approach. Additionally, the modular construction of LbL microcarriers will be used to provide more than one active agent, but with different release kinetics: Neutrophils also release reactive oxygen species (ROS) as well as HOCl leading to the activity loss of AT. Therefore, an HOCl scavenger, cefoperazone, will be integrated into the multilayer to maintain AT activity. In this proposal, the influence of the assembling sequence of both agents within the multilayer or template on their intra and extracellular functionality will be investigated. The direct comparison with another drug delivery system, complexes of Cell Penetrating Peptide (CPP) and AT, should help to establish the advantages of LbL microcarriers. Additionally, the uptake behavior and phagolysosomal processing of the LbL microcarriers with regard to an additional lipid layer surface modification will be studied. This modification is an interesting platform for the specific binding of functional molecules (antibodies, CPP) or active agents although the availability and release profiles of the multilayer-embedded active agents are still unknown. It is expected that the obtained data will support the development of new and highly specific drug delivery systems, particularly by using the multifunctional attributes of Layer by Layer technology.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
The application of LbL-microcarriers for the treatment of chronic inflammation: monitoring the impact of LbL-microcarriers on cell viability.
LbL-微载体在慢性炎症治疗中的应用:监测LbL-微载体对细胞活力的影响
DOI: 10.1002/mabi.201400405
发表时间: 2015
期刊: Macromolecular bioscience
影响因子: 4.6
作者: [M. Fichtner, C. Claus, J. Lessig-Owlanj, J. Arnhold, U. Reibetanz]
通讯作者: U. Reibetanz
DOI: 10.1021/acs.biomac.8b00360
发表时间: 2018-07
期刊: Biomacromolecules
影响因子: 6.2
作者: [Kira Scheffler;C. Claus;M. Stanifer;S. Boulant;U. Reibetanz]
通讯作者: Kira Scheffler;C. Claus;M. Stanifer;S. Boulant;U. Reibetanz
Development of LbL biopolymer capsules as a delivery system for the multilayer-assembled anti-inflammatory substance α1-antitrypsin.
开发 LbL 生物聚合物胶囊作为多层组装抗炎物质 α1-抗胰蛋白酶的递送系统
DOI: 10.1039/c3tb20390e
发表时间: 2013
期刊: Journal of materials chemistry. B
影响因子: --
作者: [V. Strehlow, J. Leßig, M. Göse, U. Reibetanz]
通讯作者: U. Reibetanz
Layer-by-Layer modified DNA Origami Nanostructures as a Smart Tool for Drug Delivery
国内基金
海外基金
基于LbL技术仿生毛囊胚芽的构建及其诱导毛囊再生的研究
  • 批准号:
    CSTB2023NSCQ-MSX0142
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2023
  • 负责人:
    陈鹏
  • 依托单位:
LBL自组装高水通量氧化石墨烯框架复合膜及资源化处理离子型稀土工业废水的机理研究
  • 批准号:
    21766011
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    40.0万元
  • 批准年份:
    2017
  • 负责人:
    张小亮
  • 依托单位:
基于单细胞LBL技术构建3D缺氧微环境研究miRNA-382在糖尿病肾病系膜组织病变中的作用
  • 批准号:
    81670669
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    王国保
  • 依托单位:
LBL改性PCL-Cellulose纳米支架激活Kc细胞的Integrin-FAK信号通路机制研究